Custom service
Peptide Drug 3D Cell Efficacy Test Platform
Test peptide drug candidates in 3d cell models for efficacy and penetration
Peptide Drug 3D Cell Efficacy Test Platform supports programmes that test peptide drug candidates in 3D cell models for efficacy and penetration. In a typical engagement we plan the spheroid and organoid penetration assays route first, confirm compatibility with 3D viability and efficacy readouts, and release 3D efficacy and penetration report on a 4–8 weeks schedule.
Chemistry is chosen for the molecule, not from a menu. Where the payload tolerates it we keep spheroid and organoid penetration assays as the primary option and hold 3D viability and efficacy readouts in reserve, so that scale-up never depends on an unproven step.
Bridging 2D potency and in-vivo efficacy
Solid-tumor penetration studies
Efficacy claims intended for regulatory submissions
Targets with no assayable readout and no purified protein available
Screening programmes close with a data package: primary screen statistics, confirmation data for each hit, counterscreen results and resynthesized material. Library lots ship with composition QC — representation and identity checks by LC-MS or NGS as the format requires.
Service Highlights
- Spheroid and organoid penetration assays as the default route, with 3D viability and efficacy readouts held as a proven fallback
- Imaging-based quantification worked into the design where the application requires it
- Every reported hit is confirmed by independent resynthesis and re-testing before it reaches you
- Analytical confirmation of every intermediate before the final release
- Library integrity (composition, representation) is measured, not assumed, before screening begins
- 3D efficacy and penetration report delivered with a complete conjugation or synthesis certificate
How the work runs
Library design
Diversity, degeneracy and deconvolution strategy for Peptide Drug 3D Cell Efficacy Test Platform are fixed in a design document.
Library synthesis or construction
The library is built with spheroid and organoid penetration assays and its composition is QC'd before screening.
Primary screening
Screening runs with 3D viability and efficacy readouts, with controls and statistics defined in advance.
Hit deconvolution
Hits are identified and ranked; counterscreens remove non-specific and promiscuous binders.
Hit confirmation
Every hit is resynthesized and re-tested; only reproducible hits advance.
Hit delivery
Confirmed hits and 3D efficacy and penetration report are delivered with the full screening data package.
Specifications & timeline
- Turnaround
- 4–8 weeks
- Typical scale
- 10^2 – 10^9 members by format
- Chemistry options
- spheroid and organoid penetration assays; 3D viability and efficacy readouts; imaging-based quantification
- Deliverable
- 3D efficacy and penetration report
- QC package
- Library composition QC, screening raw data, hit confirmation package
- Shipping
- Ambient (plates, beads) or dry ice (display libraries)
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.